Transvaginal diffusion of synthetic peptides

被引:5
作者
Basson, E. [1 ]
van der Bijl, P. [1 ]
van Eyk, A. D. [1 ]
机构
[1] Univ Stellenbosch, Fac Hlth Sci, ZA-7505 Tygerberg, South Africa
来源
EUROPEAN JOURNAL OF INFLAMMATION | 2007年 / 5卷 / 01期
关键词
human vaginal mucosa; peptides; permeability;
D O I
10.1177/1721727X0700500103
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Topical microbicide peptides are being developed to combat the transfer of HIV, but little is known about the permeation of these compounds through vaginal epithelium. The object of the present study is to investigate the in vitro permeation of synthetic transport peptides through vaginal mucosa. The permeation kinetics of three FITC (fluorescein isothiocyanate)-labelled peptides MEA-5 (Mw = 2911.4 Da), MDY-19 (Mw = 2409.5 Da) and PCI (Mw = 2325 Da) across human vaginal mucosa was studied by means of a continuous flow-through diffusion system. Permeability studies were conducted at concentrations of 1 mM, 0.75 mM and 0.5 mM in PBS buffer at 37 C and 20 C, respectively, and over a time period of 24 h, using fluorospectrophotometry as detection method. Effects of a surfactant on MDY-19 permeation and de-epithelialisation of the vaginal mucosa were also studied. Statistical tests used included an ANOVA and Duncan's multiple range test to establish steady state diffusion kinetics. All three peptides readily penetrate vaginal mucosa. Microbicides may be coupled to MDY-19 and PCI to be transported transmucosally. Although increased size of the peptide/microbicides complex may decrease mucosal permeability, this could possibly be overcome by the addition of a permeation enhancer, e.g. a surfactant. Removal of the vaginal epithelium increased the flux rates of the peptides across the mucosa and may have implications for a more rapid uptake of these and other microbicides in vivo. Concentration- and temperature-dependency of peptide flux rates must be taken into consideration when performing in vitro permeability studies.
引用
收藏
页码:15 / 20
页数:6
相关论文
共 17 条
[1]   Why consider vaginal drug administration? [J].
Alexander, NJ ;
Baker, E ;
Kaptein, M ;
Karck, U ;
Miller, L ;
Zampaglione, E .
FERTILITY AND STERILITY, 2004, 82 (01) :1-12
[2]   From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection [J].
Fleming, DT ;
Wasserheit, JN .
SEXUALLY TRANSMITTED INFECTIONS, 1999, 75 (01) :3-17
[3]   Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM) [J].
Garg, S ;
Anderson, RA ;
Chany, CJ ;
Waller, DP ;
Diao, XH ;
Vermani, K ;
Zaneveld, LJD .
CONTRACEPTION, 2001, 64 (01) :67-75
[4]  
Hancock R E, 2001, Lancet Infect Dis, V1, P156, DOI 10.1016/S1473-3099(01)00092-5
[5]   Intravaginal gels as drug delivery systems [J].
Justin-Temu, M ;
Damian, F ;
Kinget, R ;
Van den Mooter, G .
JOURNAL OF WOMENS HEALTH, 2004, 13 (07) :834-844
[6]  
MAGGIO ET, 2005, RECENT DEV INTRANASA
[7]  
MOTULSKY H, 1995, GRAPHPAD SOFTWARE
[8]   The relationship between peptide structure and antibacterial activity [J].
Powers, JPS ;
Hancock, REW .
PEPTIDES, 2003, 24 (11) :1681-1691
[9]   VAGINAL ABSORPTION OF POLYVINYL-ALCOHOL IN FISCHER-344 RATS [J].
SANDERS, JM ;
MATTHEWS, HB .
HUMAN & EXPERIMENTAL TOXICOLOGY, 1990, 9 (02) :71-77
[10]  
STRATTON P, 1993, INFECT DIS CLIN N AM, V7, P841